Prognostic biomarkers in lung cancer patients in terms of long-term survival

Year 2021, , 20 - 22, 07.03.2021

Belkis Nihan Coskun , Oğuzhan Sıtkı Dizdar , Şeniz Korkmaz Engin Ulukaya Türkkan Evrensel

https://doi.org/10.46310/tjim.875437

Abstract

Introduction:
We aimed to investigate the predictive effect of serum M30 and M65 antigens on long-term prognosis in patients with advanced stage lung cancer before and after the first dose of chemotherapy.
Methods:
Fourty eight patients with advanced stage lung cancer were included in the study. Demographic data and histopathological characteristics of the patients were recorded. Serum levels of M30 and M65 were studied in 48 patients before chemotherapy, and in 43 patients both before and 48 hours after chemotherapy. Long-term survival was evaluated using Kaplan-Meier curves. The effect of high or low M30, M65 levels and M30/M65 ratio on long-term survival was investigated.
Results: The mean age of the patients at the time of diagnosis was 57.52 ± 9.38 years. Fourty six of the 48 patients were men. While M30 value before chemotherapy was 163.23 ± 112.30 U/l; It was measured as 249.74 ± 266.67 U/l 48 hours after chemotherapy (p<0.001). While M65 value before chemotherapy was 415.97 ± 214.63 U/l; It was 656.65 ± 394.15 U/l hours after chemotherapy (p<0.001). Median survival time was calculated as 17 (2-142) months. It was found that the long-term survival of the group with a low M30/M65 ratio before chemotherapy was statistically significantly longer. It was observed that the M30/M65 ratio, or M30 or M65 alone, measured 48 hours after chemotherapy had no predictive value for long-term survival.
Conclusion:
The M30/M65 ratio before chemotherapy may be a prognostic factor for long-term survival in patients with advanced lung cancer.

Keywords

Lung cancer, M30 and M65 antigen, neoadjuvant therapy, long-term prognosis

References

• References: Caramori G, Casolari P, Cavallesco GN, Giuffre S, Adcock I, Papi A. Mechanisms involved in lung cancer development in COPD. Int J Biochem Cell Biol. 2011;43(7):1030–44. doi:10.1016/j.biocel.2010.08.022.
• Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother. 2005;59(Suppl 2):S359–62.
• Öztürk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol 2009; 9: 645-648.
• Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer? Cancer Chemother Pharmacol 2011; 68: 309-316. 12.
• Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M. Serum M30 levels are associated with survival in advanced gastric carcinoma patients. Int Immunopharmacol 2010; 10: 719-722.
• Ausch C, Buxhofer-Ausch V, Olszewski U, Schiessel R, Ogris E, Hinterberger W, et al. Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg. 2009;13(11): 2020–6. doi:10.1007/s11605-009-0992-6.
• Sen F, Yildiz I, Odabas H, Tambas M, Kilic L, Karadeniz A, et al. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma. Tumour Biol. 2015;36(2):1039–44. doi:10.1007/s13277-014-2708-0.
• Tas F, Karabulut S, Serilmez M, Yildiz I, Sen F, Ciftci R, et al. Clinical significance of serum M30 and M65 levels in melanoma. Melanoma Res. 2013;23(5):390–5. doi:10.1097/CMR.0b013e328363e4ab.
• Tas F, Karabulut S, Bilgin E, Sen F, Yildiz I, Tastekin D, et al. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. Tumour Biol. 2013;34(6):3529–36. doi:10.1007/s13277-013-0931-8.
• Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007; 56: 399-404.
• COSKUN BN, Dizdar OS, Korkmaz S et al. The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment. Contemporary Oncology, 2019, 23.4: 208.
• Chu T, Jiang L, Ying W, Han B. M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC. Clinical and Translational Oncology, 2017, 19.3: 326-331.